Practical Model-based Approaches for Phase I Oncology Trials
Phase I Oncology trials used dose-escalation to determine the maximum tolerated dose for further study. Modern model-based techniques help to acquire knowledge about the chemistry of the new drug and select appropriate dose for later phases. It offers clinicians more flexibility than more traditional designs like the 3+3. Through this introduction to advanced dose escalation methods, you will first learn about the traditional 3+3 method for dose-escalation and then gain an understanding of how Bayesian logistic regression model (BLRM) techniques can improve the traditional method.
Meet the Speaker
Dr. Satrajit Roychoudhury, Senior Director, Pfizer Inc.
Dr. Satrajit Roychoudhury is a Senior Director and a member of Statistical Research and Innovation group in Pfizer Inc. Prior to joining, he was a member of Statistical Methodology and consulting group in Novartis. He started his career as a research statistician in Schering Plough Research Institute (now Merck Co.). He has 12+ years of extensive experience in working with different phases of clinical trial. His primary expertise includes implementation of innovative statistical methodology in clinical trial. He has co-authored several publications/book chapters in this area and provided statistical training in major conferences. His area of research includes survival analysis, use of model-based approaches and Bayesian methods in clinical trials. Satrajit was a recipient of a Young Statistical Scientist Award from the International Indian Statistical Association in 2019.